-+ 0.00%
-+ 0.00%
-+ 0.00%

Cognition Therapeutics schedules FDA Type C meeting on Phase 3 endpoint for zervimesine in DLB psychosis

PUBT·09/29/2026 11:31:29
Listen to the news
Cognition Therapeutics schedules FDA Type C meeting on Phase 3 endpoint for zervimesine in DLB psychosis
  • Cognition Therapeutics will meet the FDA Division of Neurology on Oct. 20, 2026 in a Type C meeting.
  • Talks will focus on endpoint analytics and statistics for a planned Phase 3 trial of zervimesine in dementia with Lewy bodies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290730PRIMZONEFULLFEED9835344) on September 29, 2026, and is solely responsible for the information contained therein.